[{"id":"2071c41e-2dc4-4d3a-ac4b-910292b9a300","acronym":"KEYNOTE-E02","url":"https://clinicaltrials.gov/study/NCT03485209","created_at":"2022-01-26T18:56:31.320Z","updated_at":"2024-07-02T16:34:27.430Z","phase":"Phase 2","brief_title":"Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors","source_id_and_acronym":"NCT03485209 - KEYNOTE-E02","lead_sponsor":"Seagen Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • Tivdak (tisotumab vedotin-tftv)"],"overall_status":"Recruiting","enrollment":" Enrollment 692","initiation":"Initiation: 06/25/2018","start_date":" 06/25/2018","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-06-11"},{"id":"c5a7f9eb-55ee-4160-bb2f-095df5c5c5cc","acronym":"JEWEL-101","url":"https://clinicaltrials.gov/study/NCT04925284","created_at":"2023-05-03T19:04:55.692Z","updated_at":"2024-07-02T16:35:06.232Z","phase":"Phase 1","brief_title":"Study of XB002 in Subjects With Solid Tumors (JEWEL-101)","source_id_and_acronym":"NCT04925284 - JEWEL-101","lead_sponsor":"Exelixis","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HR positive • HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Avastin (bevacizumab) • samatatug zovodotin (XB002)"],"overall_status":"Recruiting","enrollment":" Enrollment 573","initiation":"Initiation: 06/07/2021","start_date":" 06/07/2021","primary_txt":" Primary completion: 06/07/2024","primary_completion_date":" 06/07/2024","study_txt":" Completion: 10/07/2024","study_completion_date":" 10/07/2024","last_update_posted":"2024-05-03"},{"id":"21fd8b64-d54b-4a80-ab6a-4592d9e0c4f7","acronym":"innovaTV 208","url":"https://clinicaltrials.gov/study/NCT03657043","created_at":"2023-05-06T23:04:06.262Z","updated_at":"2024-07-02T16:35:49.038Z","phase":"Phase 2","brief_title":"A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)","source_id_and_acronym":"NCT03657043 - innovaTV 208","lead_sponsor":"Seagen Inc.","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tivdak (tisotumab vedotin-tftv)"],"overall_status":"Completed","enrollment":" Enrollment 98","initiation":"Initiation: 03/20/2019","start_date":" 03/20/2019","primary_txt":" Primary completion: 02/08/2022","primary_completion_date":" 02/08/2022","study_txt":" Completion: 02/08/2022","study_completion_date":" 02/08/2022","last_update_posted":"2023-05-04"},{"id":"73dc5640-ccc2-462c-9a08-445c2dbdc20d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02001623","created_at":"2021-12-29T18:38:16.894Z","updated_at":"2024-07-02T16:36:19.075Z","phase":"Phase 1/2","brief_title":"Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors","source_id_and_acronym":"NCT02001623","lead_sponsor":"Seagen Inc.","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tivdak (tisotumab vedotin-tftv)"],"overall_status":"Completed","enrollment":" Enrollment 195","initiation":"Initiation: 11/30/2013","start_date":" 11/30/2013","primary_txt":" Primary completion: 05/02/2019","primary_completion_date":" 05/02/2019","study_txt":" Completion: 05/02/2019","study_completion_date":" 05/02/2019","last_update_posted":"2021-12-29"},{"id":"c19dc02f-ce25-4046-b20e-a31b79e7d5cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02552121","created_at":"2021-01-18T12:20:52.494Z","updated_at":"2024-07-02T16:36:32.203Z","phase":"Phase 1/2","brief_title":"Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors","source_id_and_acronym":"NCT02552121","lead_sponsor":"Seagen Inc.","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tivdak (tisotumab vedotin-tftv)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 11/30/2015","start_date":" 11/30/2015","primary_txt":" Primary completion: 12/13/2017","primary_completion_date":" 12/13/2017","study_txt":" Completion: 12/13/2017","study_completion_date":" 12/13/2017","last_update_posted":"2021-04-08"}]